The Hippo-signaling effector YAP1 was recently found to compensate for oncogenic RAS in certain neoplasms, suggesting so far unanticipated molecular interplays between these major signaling routes. A new study in this issue of The EMBO Journal details KRAS-dependent control of YAP1 stability as well as positive feedback regulation via the RAS/YAP1/EGFR-ligand axis as novel molecular mechanisms that could become exploitable for therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据